CIHR – Team Grant : Intervention Trial in Inflammation for Chronic Conditions – Full Application

Well-being, Health and Biomedical Discovery


Academic Unit: Inquire within unit

Memorial Deadline: Wednesday 28th, February 2024

External Deadline: Wednesday 6th, March 2024


RIS will be offering support with application development for this opportunity. Prospective applicants are encouraged to contact Dr. Jennifer Stevens ( early during the development process to discuss the services available to them

NOTE: This competition is by invitation only. Only researchers who have previously submitted an LOI can be invited.

A state of prolonged inflammation has been associated with many chronic health conditions, including but not limited to cancer, diabetes, metabolic syndrome, obesity, stroke, dementia, rheumatoid arthritis, atopic dermatitis, psoriasis, inflammatory bowel disease, asthma/chronic obstructive lung disease (COPD), allergies, endometriosis, kidney and liver diseases, neurodegenerative diseases, infectious diseases such as HIV/AIDS and blood vessel disease (atherosclerosis/thrombosis and hemostasis). It plays a role in the development of psychiatric morbidities, including anxiety and depression, and the progression and complications of premature aging and frailty. The advancement of knowledge in disease-specific fields has led to the development of therapies to control inflammation in specific conditions once diseases have been diagnosed. Control of inflammation can also be a strategy for prevention of chronic conditions as inflammation underlies the development of many of these conditions. Adoption of existing, evidence-based interventions using effective and transferable implementation strategies to optimize the delivery of healthcare is also needed to improve health outcomes for people living with or at risk of developing chronic conditions.

Building on the shared framework for inflammation research initiated through prior CIHR investments ( Health Challenge in Chronic Inflammation Phase 1 [HCCI1]), the second phase of HCCI (HCCI2) comprises two distinct funding opportunities that together will accelerate the clinical translation of solutions that target shared pathways of inflammation in chronic conditions. The first component of the HCCI2 initiative, Preparation to Trial (funded in 2021), is supporting the advancement of preclinical research towards the human intervention trial stage and a better understanding of the implementation context to enable the scale up of existing interventions. The current funding opportunity represents the second component, which will support intervention trials (see Additional Information) in humans with clinical impact on inflammation in chronic conditions and knowledge mobilization.

The overall vision of this funding opportunity is to improve the health outcomes of people living with, or at risk of developing, chronic conditions by advancing the repurposing, development, and optimization of innovative interventions. Interventions are to target biological (e.g., genetic, epigenetic), environmental (e.g., exposure to chemical products, air pollution), social (e.g., socioeconomic status, education) and behavioral (e.g., tobacco or cannabis smoking, vaping, diet) triggers of shared pathways of inflammation across two or more chronic conditions.

This funding opportunity supports the partnership with people with lived/living experience (PWLE), which involves meaningful collaboration between researchers and PWLE. In the context of this funding opportunity, PWLE are individuals with chronic conditions who are representative of the population engaged in the study project. People with chronic conditions can become partners in the proposed research by contributing to identifying research questions and priority-setting, and governance of the research and even performing certain parts of the research itself. This type of meaningful engagement helps to ensure that the research being conducted is relevant and valuable to the people that it affects.  PWLE engaged in research proposals can also collaborate with the research team to analyze and interpret research results, summarize or share the results with target audiences and policymakers or other decision-makers who may apply the results in a health or community setting. For more information about the full scope of patient engagement, please see the SPOR Patient Engagement Framework.

This funding opportunity is composed of two main types of grants:

  • Research Team Grants
  • Knowledge Mobilization Hub (KM Hub)
  • Important Dates

    Competition Letter of Intent (202303LII) Full Application (202403ITI)
    Application Deadline 2023-03-02 2024-03-06
    Anticipated Notice of Decision 2023-07-06 2024-07-08
    Funding Start Date 2023-09-01 2024-06-01


    More details on this opportunity can be found at researchnet.

Funding Sources

Canadian Institute of Health Research (CIHR)

This opportunity was posted by: RGCS

Last modified: November 28, 2022